ZYBERNO
Stock Report
Updated Aug 31, 2026

IDEAYA Biosciences, Inc. (IDYA)

Healthcare • NASDAQ

$40.11
IDEAYA Biosciences Inc. is an American oncology-focused precision medicine company headquartered in South San Francisco, California. The company's lead program darovasertib is a PKC beta inhibitor for uveal melanoma, a rare eye cancer with limited treatment options, and its portfolio includes multiple synthetic lethality programs that combine IDEAYA's compounds with external agents like MEK inhibitors.

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
33.0/100
WEAK BUSINESS
IDEAYA Biosciences, Inc. (IDYA) scores 33/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-16.5%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.05x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-17.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

IDEAYA Biosciences, Inc. (IDYA) stock report — Zyberno Score 33/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, IDYA generated -$87.65M in Owner Earnings. Capital was deployed as follows: $2.01M invested in capital expenditures. Reinvestment rate: 0.2%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:40.11
Market Cap:$3.69B

Valuation Multiples (2)

P/B Ratio:3.08x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$3.45B

Price Action & Momentum (3)

Momentum Percentile:88 / 100
% of 52-Week High:94.0%
B. Profitability Assessment

Return Metrics (5)

ROA:-15.1%
Reinvestment Rate:0.2%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:-97.9%

Yield Metrics (2)

Earnings Yield:-$4.76
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-33.2%
Latest Earnings Filed:2026-08-04

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):1.5%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:10.45x
Quick Ratio:10.45x
Cash Ratio:3.30x

Leverage Analysis (3)

Debt To Equity Ttm:0.05x
Debt-to-Equity Ratio:0.05x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:781,348,000.00
Cash And Cash Equivalents:272,589,000.00
Long Term Debt:$28.12M
Net Debt:-$239.09M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $218.71M
Linear Growth: 1.5%
📊 Click to view full IDYA Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$216.95M

Bottom Line Performance (3)

-$175.02M
Income Before Tax:$0.00
Ebitda Ttm:-214,183,000.00

Operating Expenses (5)

Operating Expenses:451,080,000.00
R And D Expense:374,007,000.00
Sga Expense:77,073,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:4,222.7%
Sga To Revenue Percentage:870.2%
Ebitda Margin:-97.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.31B
Current Assets:$864.03M
Ppe Net:8,280,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:110,794,000.00
Current Liabilities:82,677,000.00
Long Term Debt:$28.12M
Short Term Debt:$5.38M

Equity & Capital (3)

Equity:$1.20B
Retained Earnings:-$947.53M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:3,000.00
Inventory:0.00
Accounts Payable:30,508,000.00

Special Items (2)

Contract Liabilities:2,166,000.00
Stock Based Compensation:16,658,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$85.93M-$87.93M

Investment Activities (2)

Investing Cash Flow:$118.95M
Capital Expenditures Ttm:2,005,000.00

Financing Activities (3)

Financing Cash Flow:$1.18M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:274,350,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,770,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.91
-$1.91
Earnings Per Share Ttm:-$1.90

Revenue & Cash Per Share (2)

Sales Per Share Ttm:2.38
Operating Cash Flow Per Share:-$0.77

Book Value & Capital (2)

Book Value Per Share:$13.02
Cash Per Share:2.96

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.19x
Working Capital Turnover Ttm:0.28x

Receivables Management (2)

Receivables Turnover Ttm:72,903.33x
Days Sales Outstanding Ttm:0.01

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:50.91
Cash Conversion Cycle:-1,049.91
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$87.65M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.2%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):1.5%

Other Growth Rates (1)

Book Value Growth Rate (Linear):43.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:IDYA
Company Name:IDEAYA Biosciences, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:92.06M
Shares Outstanding Basic:92.06M
Shares Outstanding Diluted:92.06M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 02:01:16 UTC
Data Timestamp:2026-08-31T02:01:16.019280
Scroll to Top